ADC discovery at World ADC London 2027

Mar 8–11, 2027 London, UK ~700 attendees Website

29 organizations at World ADC London 2027 present work in ADC discovery: 15 technology and service providers, 12 drug developers and 2 academic, government and non-profit bodies. Between them they bring 21 presentations to the program. Most represented: Iksuda Therapeutics (2 on the program), Roche (2 on the program), VAR2 Pharmaceuticals (2 on the program). As of Oct 8, 2026.

All 75 organizations at World ADC London 2027 →

Showing 1–18 of 29 organizations

Organization	World ADC London 2027 Attendance
Iksuda Therapeutics Newcastle upon Tyne, UK
iksuda.com Biotech UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Araris Biotech, Oxford BioTherapeutics, Boehringer Ingelheim Clinical development Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, University of Michigan, Callio Therapeutics ADC discoveryClinical development Talk Novel ADC Designs Drive Improved Clinical Outcomes Clinical Lessons ADC discovery Workshop Thu Mar 11 1:00pm Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design Post-conference workshop for Clinical Lessons · with Oxford BioTherapeutics ADC discovery
Roche Basel, Switzerland
roche.com Large pharma Pharmaceutical and diagnostics company developing medicines in oncology, immunology, neuroscience and other areas.	Workshop Thu Mar 11 1:00pm Designing the Next Generation of ADCs: Exploring Novel Constructs & Future Combination Strategies Post-conference workshop for Discovery Clinical development
VAR2 Pharmaceuticals Copenhagen, Denmark
var2pharma.com Biotech Clinical-stage Danish biotech, spun out of the University of Copenhagen, developing therapies that target cancer-specific glycosaminoglycans.	Talk From Target to Clinic – Development & Manufacturing of the First in Class VARTUMAB ADC Manufacturing & Supply Chain ADC discovery Also Presenting at the meeting, beyond the sessions above
University of Michigan Ann Arbor, MI
umich.edu Academic & healthcare Public research university in Ann Arbor, Michigan.	Talk Antibody Design for Effective ADCs: The Multiple Impacts of Fc Engineering Pre-conference: 5th Novel Conjugates Day Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, Callio Therapeutics, Iksuda Therapeutics ADC discoveryClinical development Workshop Thu Mar 11 9:00am Accelerating ADC Model Simulation with the Power of Artificial Intelligence & Machine Learning Post-conference workshop for Pre-Clinical & Translation
Oxford BioTherapeutics Oxford, UK
oxfordbiotherapeutics.com Biotech Oncology biotech discovering new cancer targets and developing antibody and ADC therapies, including the CD205-directed ADC OBT076.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Iksuda Therapeutics, Araris Biotech, Boehringer Ingelheim Clinical development Workshop Thu Mar 11 1:00pm Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design Post-conference workshop for Clinical Lessons · with Iksuda Therapeutics ADC discovery
Queen's University Belfast Belfast, UK
qub.ac.uk Academic & healthcare Public research university in Belfast, Northern Ireland.	Workshop Introduction to ADCs Day Pre-conference: Introduction to ADCs Day Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with University of Michigan, Callio Therapeutics, Iksuda Therapeutics ADC discoveryClinical development
Amgen Thousand Oaks, CA
amgen.com Large pharma Global biotechnology company with marketed medicines in oncology, inflammation and cardiovascular disease, and research in protein therapeutics.	Talk Wed Mar 10 8:30am Precision Delivery of Therapeutics with Antibodies Through Biology, Chemistry & AI Plenary ADC discovery
Callio Therapeutics
calliotx.com Biotech Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.	Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, University of Michigan, Iksuda Therapeutics ADC discoveryClinical development
InduPro
induprotx.com Biotech Biotech developing antibody-drug conjugates against a new class of targets it calls TAPAs.	Talk TAPAs: A New Class of ADC Targets From Discovery to the Clinic Discovery Clinical development
Innovent Biologics Suzhou, China
innoventbio.com Large pharma Chinese biopharmaceutical company with marketed antibody medicines and a pipeline that includes dual-payload ADCs.	Talk Tue Mar 9 6:00pm Over the Horizon: the Dual Payload Innovation Plenary ADC discovery
SalubrisBio Gaithersburg, MD
salubrisbio.com Biotech Develops biologics for oncology and heart failure, including JK06, a biparatopic 5T4-targeted ADC with an MMAE payload.	Talk JK06 Biparatopic 5T4-Targeted MMAE ADC: Overcoming the Challenges of a Difficult Target Through Rational Design Clinical Lessons ADC discovery
Tagworks Pharmaceuticals Nijmegen, Netherlands
tagworkspharma.com Biotech Develops click-to-release cancer therapies in which a separate trigger frees the payload from tumor-bound ADCs, led by TGW101.	Talk Discovery & Development of Click-To-Release ADCs With Enhanced Therapeutic Potential Discovery
Debiopharm Lausanne, Switzerland
debiopharm.com Biotech Swiss privately owned drug developer in oncology and infectious disease, with its MultiLINK technology for ADC design.	Also Presenting at the meeting, on no published session yet
Lonza Basel, Switzerland	◆Senior Partner
lonza.com/advanced-synthesis/bioconjugates CDMOs & CROsSenior Partner Swiss CDMO that has supported more than 100 ADC programs, covering antibodies, payload-linkers, conjugation and fill-finish, plus its GlycoConnect conjugation technology.	Talk Tue Mar 9 5:30pm Lonza’s GlycoConnect® Technology for Best-in-Class ADCs: Emerging Clinical Insights Plenary ADC discoveryClinical development
WuXi XDC	◆Lead Partner
wuxixdc.com CDMOs & CROsLead Partner CRDMO dedicated to ADCs and other bioconjugates, covering antibody intermediates, payloads and linkers, and conjugated drug substance and drug product.	Talk Tue Mar 9 9:00am WuXiDARx™ Conjugation Technology & Proprietary Payload-Linker Platform: A Powerful Alliance for Next-Generation Dual Payload ADC Development Plenary ADC discoveryManufacturing & supply chain
Abzena	◇Program Partner
abzena.com CDMOs & CROsProgram Partner CDMO and CRO for ADCs, antibody-oligonucleotide and radioconjugates and other complex biologics, from discovery through commercial supply, with US and UK sites.	Sponsor In the meeting’s sponsor directory, with no session on the public program
Ajinomoto Bio-Pharma Services San Diego, CA	◇Program Partner
ajibio-pharma.com CDMOs & CROsProgram Partner CDMO offering ADC development and manufacturing built on its AJICAP site-specific conjugation, which uses Fc-affinity peptides and needs no antibody engineering or enzymes.	Sponsor In the meeting’s sponsor directory, with no session on the public program
Biocytogen Beijing, China	◇Exhibition Partner
biocytogen.com BiotechExhibition Partner Discovers fully human antibodies on its mouse platforms for partners, and supplies humanized animal models and pharmacology services for antibody and ADC programs.	Sponsor In the meeting’s sponsor directory, with no session on the public program